Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report
- 283 Downloads
Measuring tumor-specific trends in incidence is necessary to elucidate tumor-type contribution to overall cancer burden in the US population. Recently, there have been conflicting reports concerning the incidence of oligodendrogliomas (OD) and anaplastic oligodendrogliomas (AOD). Therefore, our goal was to examine trends in OD and AOD incidence and survival by age, gender and race. Data was analyzed from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2013. Age-adjusted incidence rates per 100,000 person-years with 95% confidence intervals (CI) and annual percent changes (APCs) with 95% CI were calculated for OD and AOD by age, sex and race. Survival rates were calculated for age, sex and race using a subset of the CBTRUS data. OD and AOD incidence peaked at 36–40 and 56–60 years, respectively. AOD:OD ratio increased up to age 75. Overall, OD and AOD incidence decreased [OD: APC −3.2 (2000–2013), AOD: −6.5 (2000–2007)]. OD incidence was highest in Whites but decreased significantly (2000–2013: APC −3.1) while incidence in Black populations did not significantly decrease (2000–2013: APC −1.6). Survival rates decreased with advancing age for OD, while persons aged 0–24 had the lowest survival for AOD. The current study reports a decrease in overall OD and AOD incidence from 2000 to 2013. Furthermore, AOD makes up an increasing proportion of oligodendroglial tumors up to age 75. Lower AOD survival in 0–24 years old may indicate molecular differences in pediatric cases. Thus, surveillance of tumor-specific trends by age, race and sex can reveal clinically relevant variations.
KeywordsOligodendroglioma Cancer registries Incidence Survival Time trends
Funding for CBTRUS was provided by the Centers for Disease Control and Prevention (CDC) under Contract No. 200-2016-M-90304, The Sontag Foundation, Genentech, Novocure, Celldex, AbbVie, along with the Musella Foundation, Voices Against Cancer, Elekta, and the Zelda Dorin Tetenbaum Memorial Fund, as well as private and in kind donations.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board at University Hospitals Case Medical Center. For this type of study, formal consent was not required.
This was a retrospective study using de-identified national cancer registries. Thus, formal consent was not required.
- 1.Gittleman HR, Ostrom QT, Rouse CD, Dowling JA, de Blank PM, Kruchko CA, Elder JB, Rosenfeld SS, Selman WR, Sloan AE, Barnholtz-Sloan JS (2015) Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121(1):102–112CrossRefPubMedGoogle Scholar
- 2.Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18(Suppl 1):i1–i50CrossRefPubMedGoogle Scholar
- 3.Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–i56CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636–645CrossRefPubMedGoogle Scholar
- 11.Overview of the Seer Program. In: National Cancer Institute. http://seer.cancer.gov/about/overview.html. Accessed 9 Apr 2017
- 12.Number of Persons by Race and Hispanic Ethnicity for SEER Participants - SEER Registries. In: National Cancer Institute. http://seer.cancer.gov/registries/data.html. Accessed 9 Apr 2017
- 24.Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62(5):530–537CrossRefPubMedGoogle Scholar
- 27.Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479CrossRefPubMedGoogle Scholar
- 33.Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage C-A, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre J-Y, Figarella-Branger D, and For POLA Network (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634CrossRefPubMedGoogle Scholar
- 34.Cahill DP, Sloan AE, Nahed BV, Aldape KD, Louis DN, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 125(3):531–549CrossRefPubMedGoogle Scholar
- 37.Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS (2016) “Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). J Neurooncol 130:31–42CrossRefPubMedGoogle Scholar